https://allstocknews.com/2017/11/17/comparable-company-analysis-allergan-plc-agn-senior-housing-properties-trust-snh/

Allergan plc (NYSE:AGN) shares were trading higher by 1.02 percent ($1.76) at $174.81 a piece in Thursday’s session. It had closed the previous session at $173.05. AGN trades with a P/S ratio of 3.77. This is higher than the industry’s 3.75 but lower compared with the wider sector’s 5.02. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 10.96. Shares of AGN have downtrended -21.96% in the past three months, while the S&P 500 has moved -26.95% in that time. Allergan plc (AGN) has a market cap of $58.41 billion and over the last 12 months, Allergan plc (NYSE:AGN) has gone weaker by -10.6%. During the last 52 weeks, the (NYSE:AGN) price has been as high as $256.8 and as low as $169.61. Allergan plc earnings have declined with an annualized rate of -28.7% over the last 5 years.  The average 1-year price target for Allergan plc (AGN) — averaging the work of different analysts — reveals a mean PT of $233/share. That’s a potential 33.29 increase relative to where Allergan plc (NYSE:AGN) has been trading recently. The current price is seen ranging between $171.53 and $175.5. There are brokerage firms with lower targets than the average, including one setting a price target of $191. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $280.  The collective rating of 2.2 for Allergan plc (NYSE:AGN) also leans strongly towards the neutral end of the spectrum. Of the 20 analysts surveyed by Reuters that track AGN 8 of them rate its stock a hold. The other 12, though not evenly; between analysts who think you should buy Allergan plc versus those who think you should sell it. A 12 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of AGN or, if they already own its stock, sell it.  Senior Housing Properties Trust (SNH) pulled off a 0.99 percent gain and now trades for $19.37. SNH comes in with a P/S ratio of 4.3 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (5.96) and its peers (9.44). Also, it has an estimated price-earnings (P/E) multiple of 28.74 and a trailing 12-month price-earnings (P/E) multiple of 36.62. During the last 52 weeks, the price has been as high as $22.52 and as low as $17.14. Senior Housing Properties Trust (NASDAQ:SNH) earnings have risen with a quarterly rate of 19.2% over the last 5 years. Shares of SNH have increased 1.95% in the past three monthswhile the S&P 500 has dropped -4.31% in that time.  Senior Housing Properties Trust (NASDAQ:SNH) has a market cap of $4.6 billion and over the last 12 months, SNH has risen by 6.6%. The average 1-year price target for (SNH) reveals an average price target of $20.19 per share. That’s a potential 4.23 gain from where (NASDAQ:SNH) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $16.5. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $24.  The consensus recommendation — averaging the work of 11 analysts — of 3.2 for Senior Housing Properties Trust (SNH) points to bearish case. Of the analysts surveyed by Reuters that track Senior Housing Properties Trust 6 of them rate its stock a hold. The other 5 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 2 analysts rate it as either a buy or a strong buy, while 3 believe that investors should either steer clear of (NASDAQ:SNH) or, if they already own its stock, sell it. 

https://www.bibeypost.com/pandora-media-p-upgraded-by-bmo-capital-senior-housing-properties-trust-snh-shorts-raised-by-4-81/



					
						November 16, 2017 - By Louis Casey
  Senior Housing Properties Trust (NASDAQ:SNH) had an increase of 4.81% in short interest. SNH’s SI was 4.16M shares in November as released by FINRA. Its up 4.81% from 3.97 million shares previously. With 992,000 avg volume, 4 days are for Senior Housing Properties Trust (NASDAQ:SNH)’s short sellers to cover SNH’s short positions. The SI to Senior Housing Properties Trust’s float is 1.76%. About 220,645 shares traded. Senior Housing Properties Trust (NASDAQ:SNH) has risen 16.98% since November 16, 2016 and is uptrending. It has outperformed by 0.28% the S&P500. Among 37 analysts covering Pandora Media (NYSE:P), 11 have Buy rating, 2 Sell and 24 Hold. Therefore 30% are positive. Pandora Media has $30 highest and $6.0 lowest target. $13.25’s average target is 161.86% above currents $5.06 stock price. Pandora Media had 136 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating by Aegis Capital given on Friday, January 13. The firm has “Hold” rating by RBC Capital Markets given on Friday, June 9. JP Morgan downgraded the shares of P in report on Friday, November 3 to “Neutral” rating. BMO Capital Markets maintained it with “Market Perform” rating and $11 target in Tuesday, August 1 report. The firm has “Neutral” rating by Susquehanna given on Monday, January 18. Northland Capital maintained Pandora Media Inc (NYSE:P) rating on Monday, October 26. Northland Capital has “Outperform” rating and $17 target. The stock of Pandora Media Inc (NYSE:P) has “Outperform” rating given on Friday, September 25 by Barrington Research. The firm has “Buy” rating given on Monday, October 23 by Needham. Needham maintained the stock with “Buy” rating in Tuesday, September 22 report. The firm has “Hold” rating given on Thursday, September 7 by KeyBanc Capital Markets. Senior Housing Properties Trust is a real estate investment trust . The company has market cap of $4.56 billion. The Company’s divisions include triple net senior living communities that provide short term and long term residential care and other services for residents; managed senior living communities that provide short term and long term residential care and other services for residents; properties leased to medical providers, medical related businesses, clinics and biotech laboratory tenants (MOBs), and all other, including certain properties that offer wellness, fitness and spa services to members. It has a 36.34 P/E ratio. Properties in triple net senior living communities segment include leased independent living communities, assisted living communities and skilled nursing facilities. Investors sentiment increased to 1.26 in 2017 Q2. Its up 0.32, from 0.94 in 2017Q1. It is positive, as 25 investors sold Senior Housing Properties Trust shares while 91 reduced holdings. 42 funds opened positions while 104 raised stakes. 176.71 million shares or 2.16% more from 172.98 million shares in 2017Q1 were reported. 186,924 were accumulated by Mackenzie. Nationwide Fund Advsrs invested 0.03% in Senior Housing Properties Trust (NASDAQ:SNH). Asset holds 0.01% or 15,027 shares. M&T Bank & Trust Corporation owns 19,959 shares for 0% of their portfolio. 24,635 were reported by M&R Mgmt. South Dakota Invest Council reported 154,000 shares. Bridgewater Assoc L P holds 0% or 18,937 shares in its portfolio. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Management holds 0.02% or 91,722 shares in its portfolio. Ent Fin Ser Corporation holds 0.01% of its portfolio in Senior Housing Properties Trust (NASDAQ:SNH) for 1,046 shares. Mutual Of America Cap Ltd Liability Corp owns 195,062 shares. Rafferty Asset Management Ltd has 0.02% invested in Senior Housing Properties Trust (NASDAQ:SNH) for 34,883 shares. D E Shaw & Inc holds 0% in Senior Housing Properties Trust (NASDAQ:SNH) or 27,926 shares. Guardian Mngmt invested in 16,240 shares. Renaissance Technologies Ltd Company reported 944,500 shares stake. Bollard Grp Inc Limited Liability Company stated it has 26 shares. Since May 30, 2017, it had 0 buys, and 1 insider sale for $27,540 activity. $27,540 worth of Pandora Media Inc (NYSE:P) shares were sold by MARTIN CHRISTOPHER DOUGLAS.  About 3.05M shares traded. Pandora Media Inc (NYSE:P) has declined 12.50% since November 16, 2016 and is downtrending. It has underperformed by 29.20% the S&P500. Investors sentiment increased to 1.32 in Q2 2017. Its up 0.36, from 0.96 in 2017Q1. It improved, as 44 investors sold Pandora Media Inc shares while 48 reduced holdings. 43 funds opened positions while 78 raised stakes. 284.42 million shares or 6.62% more from 266.76 million shares in 2017Q1 were reported. Beech Hill holds 0.44% or 91,175 shares. Shufro Rose & Ltd Co invested 0.02% of its portfolio in Pandora Media Inc (NYSE:P). Franklin Resources owns 0% invested in Pandora Media Inc (NYSE:P) for 15,892 shares. Hudson Bay Mgmt Lp invested in 603,800 shares or 0.11% of the stock. Ariel Invs Lc invested in 621,896 shares. Freshford Cap Management Ltd Liability Corp holds 3.03% or 1.12 million shares in its portfolio. Schwab Charles Mngmt Inc reported 715,117 shares. Zevenbergen Capital Limited Liability Co stated it has 180,700 shares. Gabelli Advisers reported 0.15% stake. Walleye Trading Ltd Liability Co holds 0.02% in Pandora Media Inc (NYSE:P) or 280,470 shares. Integral Derivatives Ltd Limited Liability Company has 0.01% invested in Pandora Media Inc (NYSE:P) for 29,886 shares. Wexford Cap Ltd Partnership reported 105,252 shares stake. Granahan Invest Mngmt Inc Ma reported 105,531 shares. Teton Advisors Inc holds 0.02% of its portfolio in Pandora Media Inc (NYSE:P) for 25,181 shares. Nordea Inv Management Ab holds 1.66 million shares. Pandora Media, Inc. is a music discovery platform, offering a personalized experience for each of its listeners wherever and whenever they want to listen to music, whether through earbuds, car speakers or live on stage. The company has market cap of $1.26 billion. The Firm delivers targeted messages to its listeners using a combination of audio, display and video advertisements. It currently has negative earnings. The Company’s divisions include Pandora-Internet Radio Service and Ticketfly. By Louis Casey Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter. 

http://standardoracle.com/2017/11/17/allergan-plc-agn-active-stock-review/

Key Statistics Allergan plc (AGN) escalated 1.02% and closed its last trading session at $174.81. Its opening price on the last trading day was $173.05. The company’s market cap is $58.41 Billion. The company has 334.11 Million shares outstanding and 331.78 Million shares were floated in market. The short ratio in the company’s stock is documented at 2.23 and the short float is around of 2.36%. Allergan plc has been given an analysts’ mean target of 230.78. 52-week High/Low The highest price AGN stock touched in the last 12 month was $256.8 and the lowest price it hit in the same period was $169.61. Stock’s distance from 52 week High is -31.93% and the distance from 52 week Low is 3.07%. Share Volume Analysis A total of 2.43 Billion shares exchanged at hands and its average trading volume is standing at 3.51 Million shares. The relative volume of the stock is 0.69. Stock Performance Allergan plc (AGN) performance during the last one year degraded -10.6 percent, while its year to date (YTD) performance showed a negative trend of -16.76 percent. The stock fell -20.23 percent over the past six months. The stock’s quarterly performance indicates a negative momentum of -21.96 percent, whereas its last one month trend is pessimistic with -6.59 percent. Its weekly performance showed upward trend of 1.05 percent. Profit Margins Analysis Profitability analysis helps a great deal in making investment decision. Net profit margin of the company was recorded at -48.6 percent, operating profit margin was -44.5 percent, while gross profit margin stands at 86.6 percent. Key Ratios Review Liquidity ratios help investors to determine a company’s ability to pay off its debts. For the most recent quarter, quick ratio was 1.1, current ratio was 1.2, LT Debt/Equity ratio was 0.4 and Total Debt/Equity ratio stands at 0.46, while Payout ratio is 0. Return on Assets, Investment and Equity Allergan plc (AGN) has a Return on Assets of -6 percent, Return on Investment of 0.1 percent and a Return on Equity of -10.8 percent. Simple Moving Average Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also helps in determining where it may be possibly heading. Now we look at the Moving Averages, the 200-day is -23.27%, the 50-day is -11.75% and the 20-day is -1.83%. EPS Growth Analysis The company’s diluted EPS for trailing twelve months was -22.57. EPS Estimate for the next year is 15.95. EPS Estimate for the next Quarter is 4.72. EPS Growth this year is 63.3 percent. Earnings and Sales Growth EPS growth for the next 5 years is 8.29 percent. Annual EPS growth Past 5 years is -28.7 percent. Annual Sales Growth in the past 5 years was 26 percent. Quarterly Revenue Growth on year-over-year basis stands at 11.4 percent. Quarterly Earnings Growth on year-over-year basis stands at -948.2 percent. Investment Valuation Ratios The company P/E (price to earnings) ratio is 0 and Forward P/E ratio is 10.96. The company P/S (price to Sales) ratio is 3.77, P/B (price to Book) ratio is 0.88, while its P/C (price to Cash) ratio stands at 10.73. Volatility Analysis If we look at the Volatility of Allergan plc (AGN), Week Volatility is 2.34%, whereas Month Volatility is at 3.06%. Technical Indicators Allergan plc (AGN)’s RSI (Relative strength index) is at 38.52, its ATR (Average True Range) value is 5.36, while its Beta factor was calculated at 1.13. Earnings Released Date The company last reported its quarterly results on Nov 01 BMO. Analysts Recommendation Allergan plc (AGN) has an Analysts’ Mean Recommendation of 2.2. Insider Ownership and Transactions Allergan plc’s insider ownership stands at 0.1 percent, while its insider transaction is -0.54 percent. Institutional Ownership and Transactions Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. Allergan plc’s institutional ownership is 85.3%, while its institutional transactions stand at -1.31%. 

https://ledgergazette.com/2017/11/17/allergan-plc-agn-issues-fy17-earnings-guidance.html


					Posted by Jennifer Salazar on Nov 17th, 2017 // No Comments  Allergan PLC. (NYSE:AGN) issued an update on its FY17 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $16.15-16.45 for the period, compared to the Thomson Reuters consensus estimate of $16.21. The company issued revenue guidance of $15.875-16.025 billion, compared to the consensus revenue estimate of $15.90 billion. Allergan PLC. (AGN) opened at $174.81 on Friday. Allergan PLC. has a 1-year low of $169.61 and a 1-year high of $256.80. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $57,553.51, a PE ratio of 11.22, a P/E/G ratio of 1.10 and a beta of 1.13.  Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, topping analysts’ consensus estimates of $4.06 by $0.09. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The business had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same quarter last year, the company posted $3.32 earnings per share. Allergan PLC.’s quarterly revenue was up 11.4% on a year-over-year basis.  analysts forecast that  Allergan PLC. will post 16.28 EPS for the current fiscal year.  The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be given a dividend of $0.70 per share. The ex-dividend date is Thursday, November 16th. This represents a $2.80 annualized dividend and a yield of 1.60%. Allergan PLC.’s dividend payout ratio (DPR) is presently -12.44%.  Allergan PLC. announced that its Board of Directors has initiated a stock buyback program on Monday, September 25th that authorizes the company to buyback $2.00 billion in    shares. This buyback authorization authorizes the company to repurchase up to 2.8% of its stock  through open market purchases. Stock  buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.  AGN has been the subject of several research reports. Citigroup Inc.  restated a buy rating and set a $280.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 20th. Deutsche Bank AG  set a $251.00 price objective on shares of Allergan PLC. and gave the stock a buy rating in a research report on Tuesday, October 17th. Piper Jaffray Companies  set a $227.00 price objective on shares of Allergan PLC. and gave the stock a hold rating in a research report on Friday, October 6th. Royal Bank Of Canada  restated a buy rating and set a $285.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 6th. Finally, J P Morgan Chase & Co  restated a buy rating and set a $275.00 price objective on shares of Allergan PLC. in a research report on Monday, October 16th. One analyst  has rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned  a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $246.73. COPYRIGHT VIOLATION WARNING: “Allergan PLC. (NYSE:AGN) Updates FY17 Earnings Guidance” was  published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/11/17/allergan-plc-agn-issues-fy17-earnings-guidance.html.  Allergan PLC. Company Profile Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

https://www.stocknewsjournal.com/2017/11/16/why-to-keeping-eye-on-allergan-plc-agn-honeywell-international-inc-hon/

Allergan plc (NYSE:AGN) gained 0.72% with the closing price of $173.05. The overall volume in the last trading session was 2.52 million shares. Company Growth Evolution: ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business. Investors who are keeping close eye on the stock of Allergan plc (NYSE:AGN) established that the company was able to keep return on investment at -5.91 in the trailing twelve month while Reuters data showed that industry’s average stands at 14.98 and sector’s optimum level is 14.37. 
     (adsbygoogle = window.adsbygoogle || []).push({});
 Allergan plc (AGN) have shown a high EPS growth of -28.70% in the last 5 years and has earnings rose of 63.30% yoy. Analysts have a mean recommendation of 2.20 on this stock (A rating of less than 2 means buy, “hold” within the 3 range, “sell” within the 4 range, and “strong sell” within the 5 range). The stock appeared $256.80 above its 52-week highs and is down -1.12% for the last five trades. The stock ended last trade at $173.05 a share and the price is up more than -17.60% so far this year. The company maintains price to book ratio of 0.86 vs. an industry average at 4.61. Its sales stood at 26.00% a year on average in the period of last five years. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued. Honeywell International Inc. (NYSE:HON) ended its day at $146.37 with the rising stream of -0.64% and its total traded volume was 2.52 million shares more than the average volume. Returns and Valuations for Honeywell International Inc. (NYSE:HON) Honeywell International Inc. (NYSE:HON), maintained return on investment for the last twelve months at 13.98, higher than what Reuters data shows regarding industry’s average. The average of this ratio is 7.53 for the industry and sector’s best figure appears 7.29. Honeywell International Inc. (NYSE:HON), at its latest closing price of $146.37, it has a price-to-book ratio of 5.33, compared to an industry average at 1.90. A lower P/B ratio could mean that the stock is undervalued. This ratio also gives some idea of whether you’re paying too much for what would be left if the company went bankrupt immediately. Honeywell International Inc. (NYSE:HON), stock is trading $147.60 above the 52-week high and has displayed a high EPS growth of 21.50% in last 5 years. The 1 year EPS growth rate is 2.70%. Its share price has risen 7.74% in three months and is down -0.33% for the last five trades. The average analysts gave this company a mean recommendation of 1.90. 

https://stocknewstimes.com/2017/11/17/investment-house-llc-raises-position-in-allergan-plc-agn.html


					Posted by Jesse Mackey on Nov 17th, 2017 // No Comments  Investment House LLC raised its position in  Allergan PLC. (NYSE:AGN) by 5.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 30,997 shares of the company’s stock after purchasing an additional 1,700 shares during the period. Investment House LLC’s holdings in Allergan PLC. were worth $6,353,000 as of its most recent filing with the SEC.  Other large investors also recently added to or reduced their stakes in the company. Boulegeris Investments Inc. boosted its holdings in  Allergan PLC. by 1.4% during the 3rd quarter. Boulegeris Investments Inc. now owns 34,066 shares of the company’s stock worth $6,982,000 after acquiring an additional 461 shares during the last quarter.  Sippican Capital Advisors boosted its holdings in  Allergan PLC. by 34.5% during the 3rd quarter. Sippican Capital Advisors now owns 5,237 shares of the company’s stock worth $1,073,000 after acquiring an additional 1,342 shares during the last quarter.  Cable Hill Partners LLC boosted its holdings in  Allergan PLC. by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after acquiring an additional 370 shares during the last quarter.  Northern Capital Management LLC boosted its holdings in  Allergan PLC. by 19.5% during the 3rd quarter. Northern Capital Management LLC now owns 15,730 shares of the company’s stock worth $3,224,000 after acquiring an additional 2,570 shares during the last quarter.  Finally, K.J. Harrison & Partners Inc boosted its holdings in  Allergan PLC. by 171.2% during the 3rd quarter. K.J. Harrison & Partners Inc now owns 25,386 shares of the company’s stock worth $5,203,000 after acquiring an additional 16,024 shares during the last quarter. Institutional investors own  81.21% of the company’s stock.  Shares of Allergan PLC. (AGN) opened at $174.81 on Friday. Allergan PLC. has a 52 week low of $169.61 and a 52 week high of $256.80. The firm has a market capitalization of $57,553.51, a P/E ratio of 11.22, a PEG ratio of 1.10 and a beta of 1.13. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18.  Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, topping analysts’ consensus estimates of $4.06 by $0.09. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same quarter last year, the firm posted $3.32 earnings per share. The firm’s revenue was up 11.4% on a year-over-year basis.  sell-side analysts forecast that  Allergan PLC. will post 16.28 EPS for the current year.  The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 1.60%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s payout ratio is -12.44%.  Allergan PLC. declared that its board has initiated a share repurchase program on Monday, September 25th that permits the company to repurchase $2.00 billion in    shares. This repurchase authorization permits the company to reacquire up to 2.8% of its stock  through open market purchases. Stock  repurchase programs are typically an indication that the company’s management believes its shares are undervalued.  ILLEGAL ACTIVITY WARNING: This piece was  posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://stocknewstimes.com/2017/11/17/investment-house-llc-raises-position-in-allergan-plc-agn.html.  A number of equities analysts have issued reports on AGN shares. Morgan Stanley downgraded shares of Allergan PLC. from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $284.00 to $228.00 in a report on Wednesday, September 20th. J P Morgan Chase & Co  set a $275.00 price target on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Sunday, October 22nd. Cowen and Company  reissued an “outperform” rating and issued a $400.00 price target on shares of Allergan PLC. in a report on Tuesday, August 29th. Zacks Investment Research downgraded shares of Allergan PLC. from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Finally, Wells Fargo & Company  reissued an “outperform” rating on shares of Allergan PLC. in a report on Monday, September 11th. One analyst  has rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned  a buy rating to the company’s stock. Allergan PLC.  has a consensus rating of “Hold” and a consensus target price of $246.73. About Allergan PLC. Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

https://allstocknews.com/2017/11/16/the-bottom-line-on-allergan-plc-agn-the-progressive-corporation-pgr/

Allergan plc (NYSE:AGN) shares were trading higher by 0.72 percent ($1.23) at $173.05 a piece in Wednesday’s session. It had closed the previous session at $171.82. AGN trades with a P/S ratio of 3.74. This is lower than the both industry’s 3.77 and the wider sector’s 5.07. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 10.85. Shares of AGN have downtrended -23.01% in the past three months, while the S&P 500 has moved -28.96% in that time. Allergan plc (AGN) has a market cap of $57.82 billion and over the last 12 months, Allergan plc (NYSE:AGN) has gone weaker by -11.91%. During the last 52 weeks, the (NYSE:AGN) price has been as high as $256.8 and as low as $169.61. Allergan plc earnings have declined with an annualized rate of -28.7% over the last 5 years.  The average 1-year price target for Allergan plc (AGN) — averaging the work of different analysts — reveals a mean PT of $233/share. That’s a potential 34.64 increase relative to where Allergan plc (NYSE:AGN) has been trading recently. The current price is seen ranging between $170.55 and $174.24. There are brokerage firms with lower targets than the average, including one setting a price target of $191. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $280.  The collective rating of 2.2 for Allergan plc (NYSE:AGN) also leans strongly towards the neutral end of the spectrum. Of the 20 analysts surveyed by Reuters that track AGN 8 of them rate its stock a hold. The other 12, though not evenly; between analysts who think you should buy Allergan plc versus those who think you should sell it. A 12 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of AGN or, if they already own its stock, sell it.  The Progressive Corporation (PGR) pulled off a 0.72 percent gain and now trades for $51.65. PGR comes in with a P/S ratio of 1.16 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (5.89) and its peers (0.63). Also, it has an estimated price-earnings (P/E) multiple of 18.28 and a trailing 12-month price-earnings (P/E) multiple of 21.55. During the last 52 weeks, the price has been as high as $51.54 and as low as $32.41. The Progressive Corporation (NYSE:PGR) earnings have risen with a quarterly rate of 8.2% over the last 5 years. Shares of PGR have increased 6.47% in the past three monthswhile the S&P 500 has gained 2.98% in that time.  The Progressive Corporation (NYSE:PGR) has a market cap of $29.98 billion and over the last 12 months, PGR has risen by 54.92%. The average 1-year price target for (PGR) reveals an average price target of $49.81 per share. That’s a potential -3.56 fall from where (NYSE:PGR) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $40. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $57.  The consensus recommendation — averaging the work of 19 analysts — of 2.4 for The Progressive Corporation (PGR) points to moderate case. Of the analysts surveyed by Reuters that track The Progressive Corporation 8 of them rate its stock a hold. The other 11 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 9 analysts rate it as either a buy or a strong buy, while 2 believe that investors should either steer clear of (NYSE:PGR) or, if they already own its stock, sell it. 

https://ledgergazette.com/2017/11/16/prudential-financial-inc-has-280-08-million-holdings-in-allergan-plc-agn.html


					Posted by Tatum Peregrin on Nov 16th, 2017 // No Comments  Prudential Financial Inc. raised its position in  Allergan PLC. (NYSE:AGN) by 1.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,366,552 shares of the company’s stock after buying an additional 14,440 shares during the quarter. Prudential Financial Inc. owned about 0.41% of Allergan PLC. worth $280,075,000 at the end of the most recent reporting period.  A number of other institutional investors have also bought and sold shares of the stock. Vident Investment Advisory LLC purchased a new position in shares of  Allergan PLC. in the 1st quarter worth about $307,000.  WFG Advisors LP boosted its holdings in shares of  Allergan PLC. by 4.1% in the 1st quarter. WFG Advisors LP now owns 656 shares of the company’s stock worth $157,000 after purchasing an additional 26 shares in the last quarter.  Tredje AP fonden boosted its holdings in shares of  Allergan PLC. by 0.9% in the 1st quarter. Tredje AP fonden now owns 68,541 shares of the company’s stock worth $16,376,000 after purchasing an additional 625 shares in the last quarter.  InterOcean Capital LLC boosted its holdings in  Allergan PLC. by 152.8% during the 1st quarter. InterOcean Capital LLC now owns 9,608 shares of the company’s stock valued at $2,296,000 after acquiring an additional 5,808 shares during the period.  Finally, Steinberg Global Asset Management boosted its holdings in  Allergan PLC. by 38.1% during the 1st quarter. Steinberg Global Asset Management now owns 11,364 shares of the company’s stock valued at $2,715,000 after acquiring an additional 3,134 shares during the period. Institutional investors and hedge funds own  81.21% of the company’s stock.  Several equities research analysts recently weighed in on AGN shares. Credit Suisse Group  reissued an “outperform” rating and issued a $286.00 target price (up previously from $274.00) on shares of Allergan PLC. in a research report on Thursday, July 20th. Mizuho  reissued a “buy” rating and issued a $267.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Wells Fargo & Company raised their price objective on Allergan PLC. to $278.00 and gave the company an “outperform” rating in a research report on Thursday, August 3rd. Royal Bank Of Canada  set a $285.00 price objective on Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, BidaskClub lowered Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. One equities research analyst  has rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned  a buy rating to the company. The company  has an average rating of “Hold” and a consensus target price of $246.73. Allergan PLC. (NYSE AGN) traded up $1.78 on Thursday, reaching $174.81. The company had a trading volume of 2,430,000 shares, compared to its average volume of 4,610,000. The stock has a market capitalization of $57,550.00, a price-to-earnings ratio of 11.14, a P/E/G ratio of 1.09 and a beta of 1.12. Allergan PLC. has a 12 month low of $169.61 and a 12 month high of $256.80. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40.  Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.06 by $0.09. The company had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.04 billion. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the business posted $3.32 earnings per share.  analysts predict that  Allergan PLC. will post 16.28 earnings per share for the current year.  Allergan PLC. declared that its Board of Directors has initiated a stock buyback plan on Monday, September 25th that allows the company to buyback $2.00 billion in    shares. This buyback authorization allows the company to reacquire up to 2.8% of its stock  through open market purchases. Stock  buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.  The business also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be given a $0.70 dividend. The ex-dividend date is Thursday, November 16th. This represents a $2.80 annualized dividend and a yield of 1.60%. Allergan PLC.’s dividend payout ratio  is currently -12.39%.  Allergan PLC. Profile Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

http://www.nasdaq.com/article/allergan-plc-agn-ex-dividend-date-scheduled-for-november-16-2017-cm877628

Allergan plc. ( AGN  ) will begin trading ex-dividend on November 16, 2017. A cash dividend payment of $0.7 per share is scheduled to be paid on December 15, 2017. Shareholders who purchased AGN prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that AGN has paid the same dividend. At the current stock price of $171.82, the dividend yield is 1.63%. The previous trading day's last sale of AGN was $171.82, representing a -33.09% decrease from the 52 week high of $256.80 and a 1.3% increase over the 52 week low of $169.61. AGN is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ  ) and Pfizer, Inc. ( PFE  ). AGN's current earnings per share, an indicator of a company's profitability, is -$22.5. Zacks Investment Research reports AGN's forecasted earnings growth in 2017 as 20.51%, compared to an industry average of -5.1%. For more information on the declaration, record and payment dates, visit the AGN Dividend History  page. Our  Dividend Calendar  has the full list of stocks that have an ex-dividend today.  Interested in gaining exposure to AGN through an Exchange Traded Fund [ETF]?   The following ETF(s) have AGN as a top-10 holding:  iShares U.S. Pharmaceutical ETF (   IHE    ) First Trust Nasdaq Pharmaceuticals ETF (   FTXH    ) PowerShares Dynamic Pharmaceuticals (   PJP    ) iShares MSCI Netherlands Index Fund (   EWN    ) iShares U.S. Preferred Stock ETF (   PFF    ).   The top-performing ETF of this group is EWN with an increase of 8.12% over the last 100 days. IHE has the highest percent weighting of AGN at 4.62%. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
 

 

https://www.stocknewsjournal.com/2017/11/15/allergan-plc-agn-from-top-to-bottom-4/

Allergan plc (AGN) is an interesting player in the Healthcare space, with a focus on Drugs – Generic. The stock has been active on the tape, currently trading at $171.82, down from yesterday’s close by -1.49%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data. Fundamental Analysis It’s important to get a feel for how any stock is actually valued on the market based on its core numbers. Allergan plc (AGN) currently trades with a market capitalization of $57.41 Billion. That value represents a market adjusting for revenues that have been growing by 11.38 % on a quarterly year/year basis as of the company’s last quarterly report. 
     (adsbygoogle = window.adsbygoogle || []).push({});
 The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For AGN, the company currently has $1.61 Billion of cash on the books, which is offset by $3.8 Billion current liabilities. You can get a sense of how sustainable that is by a levered free cash flow of $3.44 Billion over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $4.72 on a per share basis this quarter. Perhaps, that suggests something about why 87.42% of the outstanding share supply is held by institutional investors. Technical Analysis We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Allergan plc recorded a 52-week high of $256.80. It is now trading 84.98% off that level. The stock is trading $199.10 its 50-day moving average by 27.28%. The stock carved out a 52-week low down at $169.61. In recent action, Allergan plc (AGN) has made a move of -13.13% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 18.55, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 2.36% with $331.78 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of AGN. 

